Drug intelligence / Profile preview

Univ. of Jinan HDAC1 compound 11g

Development stage: Unknown
Lead developer: University of Jinan
Modality: Small Molecules

Overview

Univ. of Jinan HDAC1 compound 11g: sourced facts only. name: "Compound 11g exhibited strong inhibitory activity against HDAC1 and the A549 cancer cell line." [PMID:39395632]; target: "Compound 11g exhibited strong inhibitory activity against HDAC1 and the A549 cancer cell line." [PMID:39395632]; developer: "School of Biological Science and Technology, University of Jinan, Jinan, Shandong Province 250022, China." [PMID:39395632]; modality: "A series of Tetrahydro-β-carboline-based hydroxamate derivatives, designed as HDAC inhibitors (HDACis), were synthesized." [PMID:39395632]; stage: "Notably, 11g effectively arrested A549 cells in the G2/M phase and also increased ROS production and DNA damage, thereby inducing apoptosis." [PMID:39395632]

Targets

HDAC1 (Histone Deacetylase 1)

Beyond the preview

Go deeper on Univ. of Jinan HDAC1 compound 11g.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Univ. of Jinan HDAC1 compound 11g.